The HEXD Knockout HEK293T Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population of HEK293T cells carrying a targeted disruption of the human HEXD gene. This loss-of-function model eliminates the HEXD cofactor, providing a powerful tool for dissecting glycosaminoglycan degradation and lysosomal metabolic pathways. The polyclonal nature of the product captures a range of knockout events across the cell population, enabling robust functional studies without clonal selection bias.
HEK293T cells are a widely employed human embryonic kidney epithelial cell line derived from HEK293 cells and stably expressing the SV40 large T antigen. This adherent line offers high transfection efficiency and robust protein expression, making it a standard host for viral packaging and recombinant protein production. For lysosomal storage disease research, the HEK293T background provides a convenient and genetically tractable system in which to model the molecular consequences of HEXD disruption and to interrogate lysosomal function under defined culture conditions.
The HEXD gene encodes a catalytically inactive cofactor of hexosaminidase D, an enzyme implicated in the catabolism of glycosaminoglycans. HEXD functions within a multiprotein lysosomal complex that includes beta-hexosaminidase A (HEXA), beta-hexosaminidase B (HEXB), and the GM2 activator protein. Transcriptional control of HEXD is mediated by members of the CLEAR network, including TFEB, MITF, and TFE3. Disruption of HEXD is predicted to impair the formation or stability of the hexosaminidase complex, leading to reduced enzymatic activity, accumulation of GM2 ganglioside, lysosomal dysfunction, and impaired autophagic flux. These molecular alterations recapitulate key features of GM2 gangliosidosis and related lysosomal storage disorders.
Expression of the HEXD knockout in HEK293T cells establishes a scalable and experimentally tractable model for investigating the role of this cofactor in lysosomal homeostasis. The HEK293T background permits facile genetic manipulation, including complementation with wild-type or mutant HEXD constructs, as well as co-expression of pathway components to map protein?Cprotein interactions. The knockout cells can be subjected to lysosomal stress stimuli, such as sphingolipid loading or pH perturbation, to evaluate the contribution of HEXD to cellular resilience. In addition, the polyclonal format ensures that a spectrum of partial and complete knockout effects is represented, mirroring the genetic heterogeneity found in some patient populations.
Researchers can employ these cells in a variety of assays to study glycosaminoglycan catabolism, including western blotting and RT-qPCR to confirm HEXD ablation, immunofluorescence microscopy to assess lysosomal marker distribution, and thin-layer chromatography to quantify GM2 ganglioside accumulation. Functional readouts such as beta-hexosaminidase activity assays, lysosomal pH measurements, and autophagy flux analyses are directly applicable. The model is suited for drug discovery screens targeting GM2 gangliosidosis and for dissecting the interplay between HEXD and other lysosomal chaperones. For further information, please contact Ascent Research.
